{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:14Z","timestamp":1786119194370,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/cji.0b013e3181824d79","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T15:38:41Z","timestamp":1236267521000},"page":"675-678","source":"Crossref","is-referenced-by-count":5,"title":["Reversible, PET-positive, Generalized Lymphadenopathy and Splenomegaly During High-dose Interferon-\u03b1-2b Adjuvant Therapy for Melanoma"],"prefix":"10.1097","volume":"31","author":[{"given":"Laura","family":"Ridolfi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Cangini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Galassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Passardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Marzullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Framarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tauceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggero","family":"Ridolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210227","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.21760","article-title":"Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma","volume":"106","author":"Verma","year":"2006","journal-title":"Cancer"},{"key":"R2-8-20210227","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J Clin Oncol"},{"key":"R3-8-20210227","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"R4-8-20210227","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1200\/JCO.2001.19.9.2370","article-title":"High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH\/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694\/S9512\/C509801","volume":"19","author":"Kirkwood","year":"2001","journal-title":"J Clin Oncol"},{"key":"R5-8-20210227","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"EORTC Melanoma Group: post-surgery adjuvant therapy with intermediate doses of interferon alpha 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomized controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"key":"R6-8-20210227","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"Eastern Cooperative Oncology Group: a pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R7-8-20210227","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1200\/JCO.2002.03.052","article-title":"Mechanisms and management of toxicities associated with high-dose interferon alfa-2b. therapy","volume":"20","author":"Kirkwood","year":"2002","journal-title":"J Clin Oncol"},{"key":"R8-8-20210227","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0959-8049(03)00372-1","article-title":"Italian Melanoma Intergroup (IMI): quality of life evaluation in a randomized trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients","volume":"39","author":"Chiarion-Sileni","year":"2003","journal-title":"Eur J Cancer"},{"key":"R9-8-20210227","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1200\/JCO.2005.05.2498","article-title":"Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses","volume":"24","author":"Moschos","year":"2006","journal-title":"J Clin Oncol"},{"key":"R10-8-20210227","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/RLU.0b013e318148afa5","article-title":"PET positive generalized lymphadenopathy and splenomegaly following interferon-alfa-2b adjuvant therapy for melanoma","volume":"32","author":"Cone","year":"2007","journal-title":"Clin Nucl Med"},{"key":"R11-8-20210227","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/snuc.2002.29272","article-title":"Whole-body FDG-PET imaging in the management of patients with cancer","volume":"32","author":"Hustinx","year":"2002","journal-title":"Semin Nucl Med"},{"key":"R12-8-20210227","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1007\/s00259-005-1890-0","article-title":"Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow","volume":"32","author":"Kazama","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R13-8-20210227","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/00003072-199612000-00005","article-title":"Differentiating benign from malignant lung lesions using \u201cquantitative\u201d parameters of FDG PET images","volume":"21","author":"Hubner","year":"1996","journal-title":"Clin Nucl Med"},{"key":"R14-8-20210227","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"R15-8-20210227","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1200\/JCO.2006.09.8897","article-title":"STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma","volume":"25","author":"Ito","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CJI.0b013e3181824d79","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:47:35Z","timestamp":1786038455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002371-200809000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e3181824d79","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}